Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2014 |
| End Date: | February 2016 |
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers
assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic
Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B
inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental
State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived
neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients
and HC over 2.5 years.
assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic
Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B
inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental
State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived
neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients
and HC over 2.5 years.
IPD or HC subjects who were enrolled in a similar study about 2.5 years ago and for whom
Baseline DTI data are available.
We found this trial at
1
site
Click here to add this to my saved trials
